![](/fileadmin/_processed_/csm_Decoy_cell_cytology_f1d4d78e91.png)
Memo Therapeutics AG increases Series C financing to CHF45m
New investors Ysios Capital and Kurma Partners joined existing Series C round investors including Pureos Bioventures, Swisscanto, Vesalius...
![](/fileadmin/_processed_/csm_BMS_Evotec_072382e6ec.png)
Evotec SE cashes in €20m milestone
The partnership initiated in 2016 uses Evotec’s iPSC platform to create predictive patient-derived cell-based disease models that mimic the pathology...
![](/fileadmin/_processed_/csm_Electrochea_process_c40cabeed1.png)
Electrochaea sells biomethane reactor to Again A/S
Like German bio-CH4 producer Electrochea GmbH, Danish Again A/S is using CO2-fxing archaea, but to manufacture carbon-negative chemicals such...
![](/fileadmin/_processed_/csm_Klineo_ead54175be.jpg)
Klineo raises €2m to speed up access to cancer trials
Digital health start-up Klineo SAS (Paris) has raised €2m to improve equity of access to clinical trials. Its AI-based platform connects doctors and...
![](/fileadmin/_processed_/csm_SFactory01_Launch_044ec847f4.png)
Solar Foods starts Factory01
Following market authorisation in Singapore two years ago, the Finnish company Solar Foods Oy and the Japanese food giant Ajinomoto Group want to...
![](/fileadmin/_processed_/csm_RNF31_Pub_domain__c__RCBS_protein_data_base_62ddf70879.jpg)
Flindr Therapeutics BV secures €20m Series A financing
The Series A financing was led by V-Bio Ventures and an international syndicate that includes Johnson & Johnson Innovation – JJDC, Inc., QBIC...
![](/fileadmin/_processed_/csm_china_vs_usa_boxing-web_647d130897.jpg)
BIOSECURE Act could affect half of US biopharmaceutical development
In January 2024, the US Senate and House of Representatives introduced the BIOSECURE Act to prevent US companies that collaborate with "foreign...